Apr 10 |
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
|
Apr 2 |
MaxCyte signs strategic platform license with Be Biopharma
|
Apr 2 |
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
|
Mar 20 |
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
|
Mar 20 |
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
|
Mar 17 |
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
|
Mar 14 |
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
|
Mar 14 |
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
|
Mar 13 |
MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years
|
Mar 13 |
11 Oversold Healthcare Stocks To Buy Right Now
|